Genetic disruption of KSHV major latent nuclear antigen LANA enhances viral lytic transcriptional program  by Li, Qiuhua et al.
Virology 379 (2008) 234–244
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roGenetic disruption of KSHV major latent nuclear antigen LANA enhances viral lytic
transcriptional program
Qiuhua Li a,c, Fuchun Zhou a,b, Fengchun Ye a,b, Shou-Jiang Gao a,b,c,d,e,f,g,⁎
a Tumor Virology Program, Greehey Children's Cancer Research Institute, The University of Texas Health Science Center at San Antonio, 8403 Floyd Curl Drive, San Antonio, TX 78229, USA
b Department of Pediatrics, The University of Texas Health Science Center at San Antonio, 8403 Floyd Curl Drive, San Antonio, TX 78229, USA
c Department of Microbiology and Immunology, The University of Texas Health Science Center at San Antonio, 8403 Floyd Curl Drive, San Antonio, TX 78229, USA
d Department of Medicine, The University of Texas Health Science Center at San Antonio, 8403 Floyd Curl Drive, San Antonio, TX 78229, USA
e Department of Molecular Medicine, The University of Texas Health Science Center at San Antonio, 8403 Floyd Curl Drive, San Antonio, TX 78229, USA
f Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, 8403 Floyd Curl Drive, San Antonio, TX 78229, USA
g Tumor Virology Group, Wuhan Institute of Virology, Chinese Academy of Sciences, 44 Xiaohongshan, Wuhan, China⁎ Corresponding author. Tumor Virology Program
Research Institute, The University of Texas Health Sc
8403 Floyd Curl Drive, San Antonio, TX 78229, USA. Fax
E-mail address: gaos@uthscsa.edu (S.-J. Gao).
0042-6822/$ – see front matter © 2008 Elsevier Inc. Al
doi:10.1016/j.virol.2008.06.043a b s t r a c ta r t i c l e i n f oArticle history: Following primary infectio
Received 28 February 2008
Returned to author for revision
9 April 2008
Accepted 30 June 2008
Available online 5 August 2008
Keywords:
KSHV
LANA
Viral latency
Lytic replication
Viral transcriptional program
Reverse geneticsn, KSHV establishes a lifelong persistent latent infection in the host. The
mechanism of KSHV latency is not fully understood. The latent nuclear antigen (LANA or LNA) encoded by
ORF73 is one of a few viral genes expressed during KSHV latency, and is consistently detected in all
KSHV-related malignancies. LANA is essential for KSHV episome persistence, and regulates the expression of
viral lytic genes through epigenetic silencing, and inhibition of the expression and transactivation function of
the key KSHV lytic replication initiator RTA (ORF50). In this study, we used a genetic approach to examine the
role of LANA in regulating KSHV lytic replication program. Deletion of LANA did not affect the expression of
its adjacent genes vCyclin (ORF72) and vFLIP (ORF71). In contrast, the expression levels of viral lytic genes
including immediate-early gene RTA, early genes MTA (ORF57), vIL-6 (ORF-K2) and ORF59, and late gene
ORF-K8.1 were increased before and after viral lytic induction with 12-O-tetradecanoyl-phorbol-13-acetate
and sodium butyrate. This enhanced expression of viral lytic genes was also observed following
overexpression of RTA with or without simultaneous chemical induction. Consistent with these results,
the LANA mutant cells produced more infectious virions than the wild-type virus cells did. Furthermore,
genetic repair of the mutant virus reverted the phenotypes to those of wild-type virus. Together, these results
have demonstrated that, in the context of viral genome, LANA contributes to KSHV latency by regulating the
expression of RTA and its downstream genes.
© 2008 Elsevier Inc. All rights reserved.IntroductionKaposi's sarcoma-associated herpesvirus (KSHV), also known as
human herpesvirus 8 (HHV8), is a member of the gammaherpesvirus
family. KSHV is associated with all four clinical forms of Kaposi's
sarcoma (KS), including classical KS, African endemic KS, immuno-
suppressive organ transplant KS, and AIDS-related KS (AIDS-KS)
(Greene et al., 2007). AIDS-KS is the most common neoplasm in AIDS
patients, and has evolved as an important health concern worldwide
as a result of the spread of AIDS epidemics (Greene et al., 2007). KSHV
is also associated with several other lymphoproliferative diseases
including primary effusion lymphoma (PEL) and multicentric Castle-
man's disease (MCD)., Greehey Children's Cancer
ience Center at San Antonio,
: +1 210 562 9014.
l rights reserved.Similar to other herpesviruses, KSHV establishes a lifelong
persistent latent infection in the host following primary infection.
During latency, the virus is maintained as a non-integrated extra-
chromosomal episome, and only expresses several latent genes from
the viral latent genomic locus, which includes the latent nuclear
antigen (LANA or LNA) encoded by ORF73, vCyclin encoded by ORF72,
vFLIP encoded by ORF-K13, and a dozen of microRNAs (Cai et al., 2005;
Dittmer et al., 1998; Gao et al., 1996; Pfeffer et al., 2005; Rainbow et al.,
1997; Samols et al., 2005; Sarid et al., 1998). KSHV latency can be
disrupted by intracellular and extracellular signals, resulting in the
expression of viral lytic genes and production of infectious virions
(Deng et al., 2007). KSHV replication and transcription activator (RTA)
encoded by ORF50 is necessary and sufﬁcient for the activation of
KSHV lytic replication program (Lukac et al., 1998, 1999; Sun et al.,
1998; Xu et al., 2005). Overexpression of RTA results in the expression
of KSHV lytic genes and production of KSHV virions. A number of
chemical inducers such as 12-O-tetradecanoyl-phorbol-13-acetate
(TPA) and sodium butyrate (SB) are also capable of reactivating
KSHV from latency (Miller et al., 1996; Moore et al., 1996).
235Q. Li et al. / Virology 379 (2008) 234–244In KS lesions, the majority of the tumor cells are latently infected
by KSHV, indicating the essential role of viral latent infection in the
development of the malignancy (Greene et al., 2007). However, a
small subset of KS tumor cells also undergoes spontaneous lytic
replication. It is believed that these lytic cells could generate
infectious virions for spread to other cells, and simultaneously
produce KSHV-encoded homologs of cellular cytokines (Greene et
al., 2007). In addition, KSHV lytic replication and de novo infection
could also induce speciﬁc cellular cytokines (Carroll et al., 2004;
Qian et al., 2007; Xie et al., 2005; Ye et al., 2007). These viral and
cellular cytokines could promote tumor inﬂammation and angiogen-
esis, and enhance the proliferation, invasion and dissemination of
the tumor cells (Greene et al., 2007). As a result, both latent and lytic
phases of viral lifecycle contribute to the pathogenesis of KSHV-
induced malignancies.
In spite of intensive studies in the last decade, the mechanism
of KSHV latency remains unclear (Ganem, 2006). It is postulated
that some viral latent products might modulate KSHV latency.
Indeed, using a reverse genetic approach, we have recently
demonstrated that the viral latent protein vFLIP inhibits KSHV
lytic replication and promote viral latency by repressing the AP-1
pathway (Ye et al., 2008).
LANA is another viral latent protein that has a critical role in KSHV
latency. LANA is a 1,162 amino acids nuclear protein containing three
distinct domains: the N-terminal proline-rich domain, the central
internal repeat domain (IRD) containing several repetitive acidic
residues, and the C-terminal domainwith a nuclear localization signal
(Gao et al., 1999; Zhang et al., 2000). Using terminal repeat (TR)-
containing plasmids, it has been shown that LANA binds to the TR
sequence of the viral genome to mediate its replication, and tethers
the viral genome to cellular chromosomes for proper segregation into
daughter cells during mitosis (Ballestas and Kaye, 2001; Cotter and
Robertson, 1999; Hu et al., 2002; Krithivas et al., 2002). Transposon-
mediated genetic disruption has conﬁrmed that LANA is indeed
necessary for the establishment and persistence of KSHV episome in
mammalian cells (Ye et al., 2004).
In addition to episome persistence, LANA also modulates KSHV
latency by regulating cell growth and survival, and the expression of
viral and cellular genes. LANA targets cellular tumor suppressor p53
and pRb pathways, and oncogenic β-catenin and c-Myc pathways to
promote the growth of KSHV latent cells (Cai et al., 2006; Friborg et al.,
1999; Fujimuro et al., 2003; Liu et al., 2007; Radkov et al., 2000).
Several studies have shown that LANA regulates the expression of
cellular and viral genes through interaction with a variety of
transcriptional activators or repressors such as ATF4/CREB2, Sp1,
components of the mSin3 complex, and a newly identiﬁed centro-
meric protein KLIP1 (Krithivas et al., 2000; Lim et al., 2000; Pan et al.,
2003; Verma et al., 2004). Furthermore, LANA regulates the expres-
sion of viral genes by mediating epigenetic modiﬁcations of the viral
genome (Lu et al., 2006). More recently, it has been shown that LANA
downregulates the expression of RTA by inhibiting its promoter
activities through direct binding to the promoter and indirect binding
to other transcription factors such as RBP-Jκ and Sp1, both of which
also modulate the expression of RTA (Lan et al., 2005; Verma et al.,
2004). In addition, LANA directly interacts with RTA to prevent its
autoactivation and transactivation of other downstream viral lytic
genes (Lan et al., 2005, 2004). Together, these studies suggest that
LANA might regulate KHSV latency beyond its episome persistence
function. In this study, we assessed LANA's role in KSHV latency
focusing on LANA repression of viral lytic replication program in the
context of whole viral genome by generating a KSHV LANA deletion
mutant BAC36ΔLANA using the KSHV BAC36 genetic system (Zhou et
al., 2002). Our results revealed that deletion of LANA increased the
expression of all classes of viral lytic genes including immediate-early
(IE), early and late genes, and the production of KSHV infectious
virions. These results suggest a role of LANA in the control of KSHVlatency by repressing the expression of viral lytic genes and inhibiting
the viral lytic replication program.
Results
Generation of a KSHV LANA deletion mutant BAC36ΔLANA and its
revertant BAC36ΔLANArt
To examine the role of KSHV LANA in regulating viral transcrip-
tional program and lytic replication, we generated a LANA deletion
mutant BAC36ΔLANA and its revertant BAC36ΔLANArt by targeting
mutagenesis using the BAC36 genetic system (Zhou et al., 2002). To
delete LANA from the KSHV genome, a DNA fragment containing a
kanamycin-resistance cassette (Kanr) ﬂanked by two LoxP sites and
two 50-bpDNA fragments of KSHV sequences immediately outside the
LANA region was used for homologous recombination (Fig. 1A). An
intermediate recombinant genome, termed BAC36ΔLANA-Kan, in
which LANA was replaced with a Kanr was selected. Upon Cre-
mediated recombination, the Kanr was excised resulting in the
generation of a KSHVmutantwith LANAdeleted termed BAC36ΔLANA.
This mutant virus contains a single loxP site replacing the LANA. A
similar two-step strategy was used to generate the revertant
recombinant virus BAC36ΔLANArt. However, instead of a Kanr, we
used a zeocin-resistance cassette (Zeor) as a selection marker (Fig. 1A).
Details of the procedures were described in Materials and Methods.
Next, we carried out genetic analysis of the LANA mutant and its
revertant. Genomes of BAC36ΔLANA and BAC36ΔLANArt as well as
their intermediate recombinant viruses BAC36ΔLANA-Kan and
BAC36ΔLANArt-Zeo were analyzed by HindIII restriction enzyme
digestion. As shown in Fig. 1B, all the recombinant genomes have
restriction patterns similar to that of BAC36 except the region where
LANAwas manipulated. An 11.6-Kb DNA fragment containing LANA in
the BAC36 lane was shifted to a 9.4-Kb band in the BAC36ΔLANA-Kan
lane because of the replacement of LANA by Kanr. Of note, the new 9.4-
Kb band also coincidently overlapped with another existing 9.4-Kb
band. Upon excision of the Kanr, the 9.4-Kb bandwas shifted to an 8.2-
Kb band in the BAC36ΔLANA lane. In the BAC36ΔLANArt-Zeo lane,
because of the repair of LANA together with the introduction of a Zeor
into the locus, the 8.2-Kb band was shifted to a 12.1-Kb band, which
coincidently overlapped with another existing 12.1-Kb band. Upon
excision of the Zeor, the 12.1-Kb band was shifted to an 11.6-Kb band
that represented the repaired LANA band in the BAC36ΔLANArt lane.
Southern-blot hybridization further conﬁrmed the restriction patterns
of different recombinant viruses (Figs. 1C-E). Indeed, the LANA probe
only detected the 11.6-Kb band in the BAC36 lane, the 12.1-Kb band in
the BAC36ΔLANArt-Zeo lane, and the 11.6 band in the BAC36ΔLANArt
lane while no band was detected in the BAC36ΔLANA-Kan and
BAC36ΔLANA lanes because of the deletion of LANA (Fig. 1C). The Kanr
probe only detected the 9.4-Kb band in the BAC36ΔLANA-Kan lane
(Fig. 1D) while the Zeor probe only detected the 12.1-Kb band in the
BAC36ΔLANArt-Zeo lane (Fig. 1E). Together, these results demon-
strated that LANA was deleted in BAC36ΔLANA but repaired in
BAC36ΔLANArt, and there was no other unexpected genomic altera-
tion in these recombinant viruses.
Reconstitution of recombinant viruses in mammalian cells
To determine the phenotypes of the recombinant viruses, we
reconstituted them in HEK293 cells. Based on the percentages of GFP-
positive cells at day 2 post-transfection, we estimated 40-60%
transfection rates for all the recombinant viruses (Fig. 2A). While the
percentages of GFP-positive cells in all the cultures remained relatively
stable in the ﬁrst three days, those of BAC36ΔLANA decreased
signiﬁcantly afterward. These results conﬁrmed our previous study
demonstrating LANA's essential role in KSHV episome persistence
using a transposon-mediated insertion LANA mutant (Ye et al., 2004).
Fig. 1. Generation of a KSHV LANA deletion mutant BAC36ΔLANA and its revertant BAC36ΔLANArt. (A) A schematic illustration showing the strategy for generating BAC36ΔLANA and
BAC36ΔLANArt. A PCR fragment containing the Kanr was introduced to the BAC36 genome to replace LANA by homologous recombination resulting in the generation of an
intermediate deletion mutant BAC36ΔLANA-Kan. Removal of the Kanr by Cre-mediated recombination gave rise to BAC36ΔLANA. A similar strategy was used to construct
BAC36ΔLANArt using the Zeor as a selection marker. (B) HindIII restriction analysis of BAC36ΔLANA and BAC36ΔLANArt genomes, and their intermediate mutants, along with the
wild-type BAC36 genome. The changes of restriction bands at the LANA locus were indicated by arrowheads and detailed in the text. (C, E) Southern-blot hybridizationwith LANA (C),
Kanr (D) and Zeor (E) probes.
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Fig. 2. Expression of LANA adjacent genes following genetic deletion of LANA from the KSHV genome. (A) Reconstitution of recombinant viruses in HEK293 cells by transfection.
Images were taken at 48 h post-transfection. (B) Expression of LANA, vCyclin and vFLIP transcripts in BAC36, BAC36ΔLANA and BAC36ΔLANArt cells analyzed by RT-PCR. GAPDH was
used as a loading control. (C) Expression of LANA and vCyclin proteins in BAC36, BAC36ΔLANA and BAC36ΔLANArt cells examined by IFA using speciﬁc antibodies.
237Q. Li et al. / Virology 379 (2008) 234–244Deletion of LANA did not affect the expression of latent genes vCyclin
and vFLIP
Both vCyclin and vFLIP are adjacent to LANA in the KSHV genome.
These three genes are transcribed from the latent locus as three
transcripts: two tricistronic transcripts of 5.8-Kb and 5.4-Kb encoding
all three genes, and a 1.7-Kb biscistronic transcript encoding vCyclin
and vFLIP (Dittmer et al., 1998; Sarid et al., 1999). We used reverse
transcription PCR (RT-PCR) to detect the expression of LANA, vCyclin
and vFLIP transcripts. As shown in Fig. 2B, while LANAwas detected in
the BAC36 and BAC36ΔLANArt cells, they were absent in the
BAC36ΔLANA cells. In contrast, vCyclin and vFLIP were detected in
cells of all three recombinant viruses at similar expression levels. We
further examined the expression of LANA protein by immunoﬂuores-
cence antibody assay (IFA). As shown in Fig. 2C, while we detected
LANA-speciﬁc speckle patterns in all GFP-positive BAC36 and
BAC36ΔLANArt cells, we did not detect the same speckle patterns in
any BAC36ΔLANA cells. In contrast to LANA, vCyclin protein wasdetected in GFP-positive cells of all three recombinant viruses
(Fig. 2C). Together, these results conﬁrmed that LANA was deleted in
BAC36ΔLANA but repaired in BAC36ΔLANArt, and indicated that the
genetic manipulation procedures did not disrupt the expression of
vCyclin and vFLIP.
Deletion of LANA enhanced the expression of KSHV lytic genes
To assess the effect of LANA deletion on KSHV transcription
program, we examined the expression of a set of KSHV genes
representing different classes of viral genes including one latent
gene vCyclin, one IE gene RTA, three early genes MTA (ORF57),
ORF59 and vIL-6 (ORF-K2), and one late gene ORF-K8.1 by reverse-
transcription real-time quantitative PCR (RT-qPCR). As shown in
Fig. 3A, deletion of LANA, in general, had marginal effect on the
expression of vCyclin transcripts with or without induction with
TPA and sodium butyrate (T/B), thus further conﬁrming the results
of RT-PCR (Fig. 2B). Nevertheless, RT-qPCR did detect a 30-35%
Fig. 3. Effect of LANA deletion on KSHV transcriptional program. mRNA levels of different KSHV genes in BAC36, BAC36ΔLANA and BAC36ΔLANArt cells following induction with T/B
for 0, 24 and 48 hwere examined by RT-qPCR. The viral geneswere: (A) vCyclin, (B) RTA, (C) MTA, (D) ORF59, (E) vIL-6 and (F) ORF-K8.1. ThemRNA levels of KSHV genes in BAC36 cells
at 0 hpi were used as the baselines (1). The relative mRNA levels were ﬁrst normalized to those of GAPDH, and then to the percentages of GFP-positive cells in the cultures.
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cells at 48 h post-induction (hpi) albeit no change was observed
for the BAC36ΔLANA cells under the same condition.
RTA is a critical transactivator in KSHV switch from latency to
lytic replication. As shown in Fig. 3B, the expression of RTA
transcripts in BAC36ΔLANA cells was 3.5-fold higher than that of
BAC36 cells. Upon induction with T/B, the expression of RTA
transcripts at 48 hpi was increased 3.5- and 3.0-fold in BAC36 and
BAC36ΔLANA cells, respectively. Thus, the expression of RTA
transcripts remained 3.1-fold higher in BAC36ΔLANA cells than in
BAC36 cells following induction with T/B. The expression patterns
of RTA transcripts in BAC36ΔLANArt cells were the same as those
of BAC36 cells. These results indicated that deletion of LANA
enhanced the expression of RTA transcripts with or without
chemical induction.
We next examined the expression of other KSHV lytic genes.
MTA, a functional homologue of the Epstein-Barr virus (EBV) MTA
gene, is essential for viral lytic replication (Majerciak et al., 2007).
Co-expression of MTA and RTA synergistically activates some
promoters of KSHV early and late genes (Kirshner et al., 2000;
Malik et al., 2004; Palmeri et al., 2007). In uninduced cells, the
expression level of MTA transcripts was 2.1-fold higher in
BAC36ΔLANA cells than in BAC36 cells (Fig. 3C). While we detected
minimal differences of MTA transcripts between BAC36 and
BAC36ΔLANA cells at 24 hpi, we found that the expression of
MTA transcripts at 48 hpi was increased 4.7-fold in BAC36 cells
while that of BAC36ΔLANA cells was increased 5.4-fold compared
to uninduced cells. Thus, the expression level of MTA transcripts
was 2.4-fold higher in BAC36ΔLANA cells than in BAC36 cells at
48 hpi. Again, we found that the expression patterns of MTA
transcripts in BAC36ΔLANArt cells were the same as those of
BAC36 cells (Fig. 3C).
The expression levels of ORF59, vIL-6 and ORF-K8.1 transcripts
were also higher in the BAC36ΔLANA cells than in the BAC36 cells with
or without chemical induction though they had different expression
patterns (Figs. 3D-F). Both ORF59 and ORF-K8.1 are commonly used asKSHV lytic markers because of the availability of speciﬁc antibodies
(Chandran et al., 1998; Majerciak et al., 2006; Zoeteweij et al., 1999).
ORF59 encodes a viral accessory protein expressed in the early
phase of viral replication, whereas ORF-K8.1 encodes a glycoprotein
expressed in the late phase of viral lytic replication (Chan and
Chandran, 2000; Chandran et al., 1998). vIL-6 is one of the several
well-deﬁned KSHV genes containing the RTA-responsive element
(RRE) in their promoter regions (Deng et al., 2002). As shown in
Figs. 3D-F, the expression patterns of ORF-K8.1 transcripts were
similar to those of MTA transcripts while those of ORF59 and vIL-6
transcripts resembled to the RTA transcripts albeit the vIL-6
transcripts peaked at 24 hpi rather than at 48 hpi. The basal
expression levels of ORF59, vIL-6 and ORF-K8.1 transcripts in
BAC36ΔLANA cells were 5.0-, 3.8- and 1.6-fold higher, respectively,
than those in BAC36 cells. In BAC36 and BAC36ΔLANA cells, ORF59
transcripts were induced 5.1- and 3.5-fold while ORF-K8.1
transcripts were induced 3.0- and 5.6-fold, respectively, at 48 hpi.
Upon induction with T/B, vIL-6 transcripts were expressed at a
faster kinetics in BAC36ΔLANA cells than in BAC36 cells. At 24 hpi,
the expression levels of vIL-6 transcripts were increased 3.8-fold in
BAC36 cells, while those in BAC36ΔLANA cells were further
increased 6.0-fold on top of their higher baseline levels. Thus,
the expression levels of vIL-6 transcripts at 24 hpi remained at 6.0-
fold higher in BAC36ΔLANA cells than in BAC36 cells. Interestingly,
while the expression levels of vIL-6 transcripts at 48 hpi in
BAC36ΔLANA cells decreased slightly from the previous time point,
those of BAC36 cells were further increased 2.3-fold. Nevertheless,
the expression levels of vIL-6 transcripts at 48 hpi in BAC36ΔLANA
cells remained at higher levels than those of BAC36 cells (Fig. 3E).
As expected, the expression patterns of ORF59, vIL-6 and ORF-K8.1
transcripts in BAC36ΔLANArt cells were similar to those of
BAC36ΔLANA cells (Figs. 3D-F). Together, these results indicated
that deletion of LANA also enhanced the expression of RTA
downstream lytic genes. However, the expression patterns of
these genes varied according to the individual viral lytic genes,
possibly reﬂecting their differential expression kinetics.
Fig. 4. Effect of LANA deletion on the expression of KSHV lytic proteins. (A, B) Percentages of actual MTA- (A) and ORF59-positive cells (B) detected by immunoﬂuorescence antibody
assay in uninduced and T/B-induced BAC36, BAC36ΔLANA and BAC36ΔLANArt cells.
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Since we had observed enhanced expression levels of KSHV lytic
transcripts following deletion of LANA from the KSHV genome, we
further determined whether these results could be translated into
protein levels. We carried out IFA staining for MTA and ORF59 proteins
using speciﬁc antibodies in uninduced or T/B-induced cells. We
detected low numbers of MTA- and ORF59-positive cells at about
1.0-1.5% in uninduced BAC36 cells, indicating that themajority of these
cells were at tight latency. In contrast, BAC36ΔLANA cells were more
leaky for the expression of viral lytic proteins, and had about 12-14.0%
MTA- and ORF59-positive cells, respectively, indicating a reduced level
of repression of viral lytic transcriptional program in these cells
(Figs. 4A and B). The enhanced expression levels of KSHV lytic proteins
in BAC36ΔLANA cells were also observed following inductionwith T/B.
As shown in Figs. 4A and B, the percentages of both MTA- and
ORF59-positive cells were increased 5.0-fold in BAC36 cells, and 2.0-
and 2.7-fold, respectively, in BAC36ΔLANA cells following induction
with T/B. Thus, BAC36ΔLANA cells had 4.4- and 5.8-fold more MTA-
and ORF59-positive cells, respectively, than BAC36 cells followingFig. 5. Expression of KSHV lytic genes following different induction methods of KSHV lytic re
lytic MTA and ORF-K8.1 transcripts in BAC36 cells. No induction was observed with the LANA
baculoviruses. The mRNA levels of KSHV genes in the mock-infected cells were used as the ba
BAC36ΔLANArt cells following induction with T/B, BacK50, or combination of both methods
ORF-K8.1. The mRNA levels of KSHV genes in BAC36 cells at 0 hpi were used as the baseline
GAPDH, and then to the percentages of GFP-positive cells in the cultures.induction with T/B. The patterns of MTA- and ORF59-positive cells in
BAC36ΔLANA cells were almost the same as the BAC36 cells (Fig. 4).
These results demonstrated that deletion of LANA enhanced the
expression of viral lytic proteins with and without inductionwith T/B.
LANA repressed multiple stages of KSHV lytic replication
Our results indicated that LANA regulated the expression of RTA
during both KSHV latency and lytic replication (Fig. 3B). Previous
studies have shown that during T/B-induction of KSHV lytic replica-
tion, a series of viral and cellular events occur, including epigenetic
remodeling of KSHV genome, and induction of cellular transcriptional
factors and expression of RTA, that synergistically culminate in the
activation of KSHV lytic cascade (Chen et al., 2001; Sun et al., 1999;
Wang et al., 2004; Xie et al., 2007). Since RTA is necessary and
sufﬁcient for activating KSHV lytic transcription program, we directly
examined the effect of LANA deletion on RTA transactivation of KSHV
lytic genes. We induced KSHV lytic replication by infecting the cells
with BacK50, a RTA baculovirus, known to effectively reactivate KSHV
from latency (Vieira and O'Hearn, 2004). As shown in Fig. 5A,plication program. (A) BacK50 but not control Bac-WT induced the expression of KSHV
and vCyclin transcripts. Viral transcripts were analyzed at 48 h after infection with the
selines (1). (B–D)mRNA levels of different KSHV lytic genes in BAC36, BAC36ΔLANA and
for 48 h were examined by RT-qPCR. The viral genes were: (B) MTA, (C) ORF59, and (D)
s (1). In all the experiments, the relative mRNA levels were ﬁrst normalized to those of
Fig. 6. Effect of LANA deletion on the production of KSHV infectious virions. BAC36,
BAC36ΔLANA and BAC36ΔLANArt cells were induced with T/B alone, or together
with RTA for 96 h. Supernatants were then titrated for infectious virions by
infecting HEK293 cells. The relative virus titers were calculated using T/B-induced
BAC36 cells as the baseline (1).
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13.6-fold while simultaneously inducedMTA and ORF-K8.1 transcripts
by 4.2- and 2.3-fold, respectively. The expression of LANA and vCyclin
transcripts was not induced following RTA expression. In contrast to
the RTA baculovirus, infection with a wild-type baculovirus (Bac-WT)
without containing RTA had no effect on the expression of any viral
transcripts, indicating that the observed induction of MTA and
ORF-K8.1 transcripts was caused by the overexpression of RTA rather
than any unspeciﬁc effects caused by baculovirus infection. As shown
in Figs. 5B-D, overexpression of RTA increased the expression of MTA,
ORF59 and ORF-K8.1 transcripts by 7.2-, 13.4- and 9.4-fold, respec-
tively, in BAC36 cells. As expected, the expression levels of MTA,
ORF59 and ORF-K8.1 transcripts without any induction were already
higher in BAC36ΔLANA cells than in BAC36 cells by 2.1-, 5.0- and
5.2-fold, respectively. Following induction with RTA, the expression
levels of these transcripts in BAC36ΔLANA cells were further increased
by 6.2-, 11.0- and 3.5-fold, respectively. Overall, the expression levels
of MTA, ORF59 and ORF-K8.1 transcripts were 1.8-, 4.1- and 1.9-fold
higher in BAC36ΔLANA cells than BAC36 cells, respectively, following
induction with RTA. It was noted that both ORF59 and ORF-K8.1
transcripts had higher expression levels following induction with RTA
than with T/B in both BAC36 and BAC36ΔLANA cells while the MTA
transcripts had similar expression levels following induction with
both methods in these cells. These results were consistent with those
reported in another study (Vieira and O'Hearn, 2004), and suggested
that the initial induction of RTA might be a “limiting factor” during
T/B-induced KSHV lytic replication. Indeed, results of RT-qPCR
indicated that the induction of RTA transcripts was not very efﬁcient
following T/B treatment (Fig. 3B). When we combined the induction
methods of T/B and RTA, the expression levels of MTA, ORF59 and
ORF-K8.1 transcripts were increased by 15.9-, 41.5-, and 36.1-fold,
respectively, in BAC36 cells, and 41.1-, 186.5- and 43.4-fold, respec-
tively, in BAC36ΔLANA cells, using uninduced BAC36 cells as the
baseline, suggesting a synergistic effect of the two induction methods.
While the expression levels of MTA and ORF59 transcripts remained
substantially higher in BAC36ΔLANA cells than in BAC36 cells, the
difference for the ORF-K8.1 transcripts became minimal following the
combined induction of T/B and RTA (Fig. 5D). Thus, the expression of
ORF-K8.1 appeared to have reached the maximum limit following
combined induction with these two methods. Again, we found that
results from the BAC36ΔLANArt cells were similar to those of BAC36
cells, indicating that the observed enhanced expression of viral genes
were indeed due to the deletion of LANA but not because of any
alterations in other parts of the viral genome. Together, these results
indicated that LANA also repressed the expression of RTA downstream
viral lytic genes.
Deletion of LANA increased the production of KSHV infectious virions
The above experiments demonstrated that deletion of LANA from
the KSHV genome increased the expression of KSHV lytic genes. We
further determined whether this enhanced viral lytic replication
program resulted in the increased production of KSHV infectious
virions. We induced the cells with T/B alone or together with BacK50.
At 96 hpi, the cultured supernatants were collected and titrated for
infectious virions by infecting 293T cells. BAC36 cells typically
generated 104 GFP-positive cells units (GFU) following induction
with T/B (Zhou et al., 2002). As shown in Fig. 6, BAC36ΔLANA cells
produced 3.4-fold more infectious virions than BAC36 cells following
induction with T/B. Consistent with the gene expression results
(Fig. 6), induction with both RTA and T/B further increased the yields
to 2.1- and 4.8-fold in BAC36 and BAC36ΔLANA cells, respectively,
when we used the T/B-induced BAC36 cells as the baseline (Fig. 6).
BAC36ΔLANArt cells produced similar amounts of infectious virions as
the BAC36 cells under both induction conditions. Thus, deletion of
LANA increased the production of KSHV infectious virions followinginduction of viral lytic replication. These results also demonstrated
that LANA was not an essential gene for viral lytic replication and
virion production.
Discussion
Extensive studies have shown that the major KSHV latent
protein LANA is a multifunctional protein regulating different
phases of viral lifecycle. LANA is essential for KSHV latency as it
plays a critical role in KSHV episome persistence by mediating
episome replication, and episome segregation into daughter cells
during mitosis (Ballestas and Kaye, 2001; Cotter and Robertson,
1999; Hu et al., 2002; Krithivas et al., 2002). LANA also regulates
cell growth and survival by targeting multiple cellular tumor
suppressor and oncogenic pathways, including p53, pRb, β-catenin
and c-Myc pathways, and thus further contributes to KSHV latency
(Cai et al., 2006; Friborg et al., 1999; Fujimuro et al., 2003; Liu et
al., 2007; Radkov et al., 2000). Recently, several studies have
shown that LANA might control KSHV latency by repressing KSHV
lytic transcriptional program (Lan et al., 2004, 2005; Verma et al.,
2004). While these studies were mostly carried out by over-
expressing the viral gene, their results have suggested a novel
function of LANA in regulating KSHV latency. In the current study,
we have examined the role of LANA in regulating KSHV lytic
transcriptional program in the context of whole viral genome. We
used a genetic approach to delete LANA from the KHSV genome,
and assessed the effect on viral replication. Our results showed that
deletion of LANA from the viral genome indeed increased the
expression of KSHV lytic genes during both viral latency and lytic
replication. As a result, LANA deletion mutant cells produced more
KSHV infectious virions. These results have conﬁrmed that, in
addition to regulation of KSHV episome persistence, and cell
growth and survival, LANA also controls KSHV latency by
repressing viral lytic transcriptional program (Lan et al., 2004).
During KSHV latency, only a handful of KSHV genes, including
LANA, vCyclin and vFLIP, and the recently described viral microRNAs
are expressed while viral lytic genes are generally silent (Greene et al.,
2007). It is believed that such tight control of expression of KSHV lytic
genes is regulated by one or more of the viral products expressed
during viral latency (Ye et al., 2008). Indeed, by means of the same
genetic approach used in this study, we have recently shown that
KSHV latent gene vFLIP controls viral latency by repressing KSHV lytic
transcriptional program (Ye et al., 2008). vFLIP represses the
expression of KSHV lytic genes, including the key lytic switch gene
RTA, by inhibiting the activation of AP-1, which is an essential cellular
transcriptional factor for activating the expression of several viral lytic
genes and viral lytic replication program (Pan et al., 2006; Wang et al.,
241Q. Li et al. / Virology 379 (2008) 234–2442004; Xie et al., 2007). In the current study, we have shown that
deletion of LANA also increases the expression of KSHV lytic genes
including RTA in uninduced KSHV-infected cells. These results
conﬁrmed those obtained in previous studies using single viral gene
(Lan et al., 2004, 2005), and indicated that, similar to vFLIP, LANA also
controls viral latency by repressing KSHV lytic transcriptional
program. Thus, KSHV at least uses two viral latent proteins LANA
and vFLIP to promote viral latency by controlling viral lytic transcrip-
tional program. It remains to be determined whether these two viral
proteins carry out these similar functions independently or synergis-
tically at different phases of viral lifecycle.
While the mechanism of LANA controls KSHV latency might be
complex, previous studies have shown that LANA represses the
expression of KSHV lytic genes through epigenetic silencing of KSHV
genome, and inhibition of the expression and transactivation function
of RTA (Lan et al., 2004, 2005; Lu et al., 2006; Verma et al., 2004).
Interestingly, a LANA-deﬁcient murine gammaherpesvirus 68 had
impaired viral replication in murine ﬁbroblasts albeit an enhanced
kinetics of viral gene expression because of p53 induction and cell
death (Forrest et al., 2007). Thus, the detailed mechanism of LANA
repression of KSHV lytic transcriptional program during viral latency
remains to be further elucidated. Of particular interest is the
comparison of speciﬁc epigenetic modiﬁcations of KSHV genome
and promoters of speciﬁc viral latent and lytic genes in the LANA
deletion mutant and wild-type virus cells. Such information could
provide further insights into the mechanism of LANA regulation of
cellular genes during KSHV latency.
KSHV lytic replication is a multistep process usually initiated with
epigenetic remodeling of the viral genome, induction of speciﬁc
cellular transcriptional factors and RTA (Chen et al., 2001; Sun et al.,
1999; Wang et al., 2004; Xie et al., 2007). Treatment of cells harboring
wild-type virus with T/B induced KSHV lytic replication, indicating
that these chemical agents were at least sufﬁcient to partially release
different blocks of viral lytic replication, including the repression
effects of vFLIP and LANA, and initiate the viral lytic replication
cascade. Nevertheless, deletion of LANA from the KSHV genome
further enhanced the viral lytic transcriptional program upon
chemical induction, indicating that LANA might exert its repression
effects at various stages of viral lytic replication, and treatment with
T/B was not sufﬁcient to completely release these repression effects.
Indeed, in the T/B induction experiments, we showed that LANA
regulated the expression of RTA while in the RTA induction
experiments, we showed that LANA also regulated the transactivation
function of RTA. Furthermore, a synergistic effect was observed when
the cells were induced with both T/B and RTA. Together, these results
conﬁrm the existence of multiple blocks in KSHV lytic replication, and
suggest that inductionwith neither method is sufﬁcient to completely
overcome these blocks. Interestingly, KSHV lytic genes remained
expressed at higher levels in the LANA deletionmutant evenwhen the
cells were induced with both T/B and RTA, indicating that induction
with bothmethods was also not sufﬁcient to completely overcome the
blocks imposed by LANA alone in the wild-type virus. Thus, we
conclude that the mechanism of KSHV regulation of latency and lytic
replication is rather complex, and the optimal combination for
inducing KSHV lytic replication remains to be uncovered.
Our results have also shown that individual KSHV lytic genes are
differentially regulated by LANA. It was interesting that deletion of
LANA accelerated the expression kinetics of vIL-6 following induction
with T/B. At 24 hpi, vIL-6 was induced to much higher levels in
BAC36ΔLANA cells than BAC36 cells. vIL-6 was also induced to a
higher level in BAC36ΔLANA cells than other KSHV lytic genes
including RTA in cells of both mutant and wild-type viruses. We
postulated that the expression of vIL-6 could also be regulated at a
RTA-independent mechanism, at least at the early stage of viral lytic
replication, and this mode of expression were highly regulated by
LANA. In fact, an RTA-independent activation mechanism has beendescribed for regulating the expression of vIL-6 (Chatterjee et al.,
2002). Further examination of LANA and RTA transcriptional and
functional regulation of KSHV genes at thewhole genome scale should
promise to reveal insights into the expression control of viral genes,
and the mechanism of KSHV latency and reactivation.
Materials and methods
Cell lines and cell culture
Human embryonic kidney 293 (HEK293) cells were maintained in
Dulbecco's modiﬁed Eagle's medium (DMEM) supplementedwith 10%
fetal bovine serum (FBS) and 50 μg/ml of gentamycin. The Spodoptera
frugiperda pupal ovarian cell line Sf9 was grown at 27 °C in complete
BaculoGold TNM-FH insect medium (BD Biosciences, San Jose, CA).
Generation of KSHV LANA deletion mutant
The strategy for generating the KSHV LANA deletion mutant and
its revertant was illustrated in Fig. 1A. The procedures were
essentially carried out as previously described (Zhou et al., 2002).
Brieﬂy, a linear DNA fragment containing a Kanr ﬂanked by loxP
sites was PCR-ampliﬁed with primers LANAK-F and LANAK-R that
carry the homologous recombination sequences immediately out-
side the LANA locus (Table 1). The puriﬁed PCR fragment was
electroporated into competent E. coli containing the BAC36 genome
and the pKD46 plasmid to facilitate homologous recombination
(Datsenko and Wanner, 2000). After the ﬁrst round of homologous
recombination, the kanamycin- and chloramphenicol-resistant
transformants containing the intermediate recombinant KSHV
LANA deletion mutant, termed BAC36ΔLANA-Kan, were isolated
and analyzed by HindIII digestion (Fig. 1B). The Kanr was removed
from the intermediate mutant by Cre-mediated recombination
upon transfection of the plasmid pCTP-T expressing the Cre
recombinase into the BAC36ΔLANA-Kan E. coli (Saeki et al., 2001).
The resulting recombinant KSHV LANA deletion mutant, termed
BAC36ΔLANA, was further veriﬁed by HindIII restriction digestion
and Southern-blot hybridization (Figs. 1C-E).
The BAC36ΔLANA revertant was constructed with similar strategy
(Fig. 1A). For this purpose, a 4.7-Kb HindIII-EcoRI DNA fragment
containing the entire LANA-coding frame and a Zeor was generated.
Two PCR reactions were carried out using BAC36 as a template: a
HindIII-PacI DNA fragment ampliﬁed with primers LANAF and
PacI-LANAR, and an EcoRI-PacI fragment ampliﬁed using primers
PacI-LANAL and EcoRI-LANAL (Table 1). The two PCR fragments were
puriﬁed, ligated and cloned into the HindIII and EcoRI sites of
pBluescript II KS (Stratagene, La Jolla, CA). The resulting plasmid DNA
was digested with PacI, and a Zeor was then cloned into this site to
generate plasmid pBSK-HZeoE. Following HindIII and EcoRI digestion
of the pBSK-HZeoE DNA, the 4.7-Kb HindIII-EcoRI fragment was gel
puriﬁed, and electroporated into E. coli containing the BAC36ΔLANA
genome and the pKD46 plasmid. Upon homologous recombination,
zeocin- and chloramphenicol-resistant colonies containing an inter-
mediate revertant recombinant, termed BAC36ΔLANArt-Zeo, was
selected. The Zeor was then removed by Cre-mediated recombination.
The resulting mutant revertant construct, termed BAC36ΔLANArt, was
veriﬁed by HindIII restriction digestion and Southern-blot
hybridization (Figs. 1B-E).
Restriction analysis and Southern-blot hybridization
DNA preparations of different recombinant viruses were digested
with HindIII restriction enzyme, separated on 0.8% agarose gels by
electrophoresis, and transferred to Zeta-Probe GT membranes (Zhou
et al., 2002). The membranes were hybridized with 32P-labeled LANA,
Kanr and Zeor probes, and speciﬁc signals were detected with a
Table 1
Primers used for genetic manipulation, RT-qPCR and RT-PCR
Gene Application Primer
Kanr Mutagenesis LANAK-F: 5′-accgcctccataatttactttggttgtcagaccagatttcccgaggatggtgtaggctggagctgcttc-3′
Kanr Mutagenesis LANAK-R: 5′-cggcgacggtggcttctagggaggaaaaagggggagaggtgtggcttttacatatgaatatcctccttag-3′
LANA HindIII-PacI fragment Mutagenesis LANAF: 5′-tttaagcttcatgggttattggccgtttctgtttct-3′
LANA HindIII-PacI fragment Mutagenesis PacI-LANAR: 5′tttttaattaagtcatttcctgtggagagtccccaggacct-3′
LANA EcoRI-PacI fragment Mutagenesis PacI-LANAL: 5′tttttaattaaaagccacacctctccccctttttcctc-3′
LANA EcoRI-PacI fragment Mutagenesis EcoRI-LANAL: 5′-tttgaattctaacttacgcatatgcgaagtaagaga-3′
vCyclin RT-qPCR vCyclin-F: 5′-gctgataatagaggcgggcaatgag-3′
vCyclin RT-qPCR vCyclin-R: 5′-gttggcgtggcgaacagaggcagtc-3′
RTA RT-qPCR ORF50-F: 5′-cacaaaaatggcgcaagatga-3′
RTA RT-qPCR ORF50-R: 5′-tggtagagttgggccttcagtt-3′
MTA RT-qPCR ORF57-F: 5′-acgaatcgagggacgacg-3′
MTA RT-qPCR ORF57-R: 5′-cgggttcggacaattgct-3′
vIL-6 RT-qPCR ORF-K2-F: 5′-acccttgcagatgccgg-3′
vIL-6 RT-qPCR ORF-K2-R: 5′-ggatgctatgggtgatcgatg-3′
ORF59 RT-qPCR ORF59-F: 5′-cgagtcttcgcaaaaggttc-3′
ORF59 RT-qPCR ORF59-R: 5′-aagggaccaactggtgtgag-3′
ORF-K8.1 RT-qPCR ORF-K8.1-F: 5′-aaagcgtccaggccaccacaga-3′
ORF-K8.1 RT-qPCR ORF-K8.1-R: 5′-ggcagaaaatggcacacggttac-3′
GAPDH RT-qPCR GAPDH-F1: 5′-cccctggccaaggtcatcca-3′
GAPDH RT-qPCR GAPDH-R1: 5′-acagccttggcagcgccagt-3′
vCyclin RT-PCR vCyclin-F: 5′-gactgcctctgttcgccacgcc-3′
vCyclin RT-PCR vCyclin-R: 5′-gccaggaatacaacctagaacc-3′
vFLIP RT-PCR vFLIP-F: 5′-cgtctacgtggagaacagtgagctg-3′
vFLIP RT-PCR vFLIP-R: 5′-ctgggcacggatgacagggaagtg-3′
LANA RT-PCR LANA-F: 5′-tacggttggcgaagtcacatc-3′
LANA RT-PCR LANA-R: 5′-cctcgcagcagactacacctccac-3′
GAPDH RT-PCR GAPDH-F2: 5′-gaaggtgaaggtcggagtc-3′
GAPDH RT-PCR GAPDH-R2: 5′-gaagatggtgatgggatttc-3′
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Piscataway, NJ).
Reconstitution of recombinant viruses in mammalian cells
HEK293 cells were plated in T-75 ﬂasks one day before transfec-
tion. Cells at 70-80% conﬂuency were transfected with 25 μg of a fresh
DNA preparation of a recombinant virus using Targefect-293 F-2
Transfection Reagent according to the instructions of the manufac-
turer (Targeting Systems, El Cajon, CA). All DNA preparations of
different recombinant viruses were veriﬁed for integrity by restriction
analysis and Southern-blot hybridization (Fig. 1). At 24 h post-
transfection, the transfected cells were split into either T-25 ﬂasks or
coverslips in 24-well plates at 70-80% conﬂuency. The transfection
efﬁciency was monitored by counting the percentages of GFP-positive
cells at 48 h post-transfection.
Baculovirus
Recombinant baculovirus BacK50 expressing KSHV RTA was
generously provided by Dr. Jeffrey Vieira at the University of
Washington, Seattle, WA and propagated in Sf9 cells (Vieira and
O'Hearn, 2004). Virus was collected by centrifugation to remove the
cell debris when the majority of the cells underwent lysis. The
resulting supernatants containing infectious BacK50 were aliquoted
and stored at -80 °C as stocks. A wild-type baculovirus without RTA
Bac-WT was used as a control.
Induction of viral lytic replication
To induce viral lytic replication, cells of different recombinant
viruses were treated with 23 ng/ml of TPA and 3mM sodium butyrate.
To examine LANA's effect on RTA transactivation of other downstream
viral lytic genes, cells were also infected with BacK50 or Bac-WT with
or without T/B. For the later experiments, cells were infected with
BacK50 for 2 h before the addition of T/B. To examine the expression of
viral genes, cells were collected at different hpi and examined for theexpression of viral transcripts and proteins. To examine the produc-
tion of virions, supernatants collected from the cultures at 96 hpi were
centrifuged to remove cell debris, and used to inoculate HEK293 in
24-well plates in triplicates. The numbers of GFP-positive cells
generated from 1 ml of supernatant reﬂecting the relative viral titers
(GFU) were determined as previously described (Gao et al., 2003; Pan
et al., 2006).
Reverse-transcription real-time quantitative PCR (RT-qPCR) and reverse
transcription PCR (RT-PCR)
Total RNA samples from triplicates were prepared using the SV
total RNA Isolation System (Promega Corporation, Madison,WI). cDNA
samples were reverse-transcribed from total RNA using the Super-
Script III First-Strand Synthesis System (Invitrogen, Carlsbad, CA), and
primed with random hexamers. Real-time PCR reactions were carried
out for RTA, MTA, vIL-6, ORF59, ORF-K8.1, and GAPDH as described
previously (Yoo et al., 2005). The primers are listed in Table 1. Brieﬂy,
each real-time PCR (qPCR) reaction was carried out in a total reaction
volume of 20 μl consisting of SYBR-PCR master mix, the cDNA
template and gene-speciﬁc primers in a DNA Engine Opticon 2
Continuous Fluorescence Detector (Bio-Rad Laboratories,
Hercules, CA). PCR reactions were carried out in triplicates for each
sample. The relative mRNA levels were ﬁrst normalized to those of
GAPDH, and then to the percentages of GFP-positive cells in
the cultures.
RT-PCR reactions were also carried out to detect the expression of
vCyclin, vFLIP, and LANA transcripts in HEK293 cells harboring BAC36,
BAC36ΔLANA and BAC36ΔLANArt as previously described (Ye et al.,
2004). The primers were listed in Table 1. The speciﬁc PCR products
were examined on 2% agarose gels.
Immunoﬂuorescence antibody assay (IFA)
IFAwas carried out as previously described (Ye et al., 2004). Brieﬂy,
cells on glass coverslips were ﬁrst ﬁxed with 4% paraformaldehyde in
phosphate-buffered saline (PBS) at 4 °C for 20 min, and then
243Q. Li et al. / Virology 379 (2008) 234–244permeabilized with 0.5% Triton X-100 in PBS at 4 °C for 10 min. The
cells were blocked with 3% bovine serum albumin in PBS at 37 °C for
1 h followed by incubation with a primary antibody at 37 °C for 1 h.
Speciﬁc signal was detected by incubating the cells with a secondary
antibody at 37 °C for another 45 min followed by examinationwith an
Axiovert Fluorescence Microscope (Carl Zeiss, Maple Grove, MN).
Rabbit polyclonal antibodies were used to detect vCyclin and MTA
(a gift of Dr. Zhiming Zheng). A goat anti-rabbit IgG Rhodamine
conjugate was used to reveal the speciﬁc signals (Santa Cruz
Biotechnology, Santa Cruz, CA). A mouse monoclonal antibody was
used to detect ORF59 protein (a gift of Dr. Bala Chandran), and speciﬁc
signals were revealed with a goat anti-mouse IgG Alexia Fluor 568
conjugate (Invitrogen). LANA was detected with a rat monoclonal
antibody (ABI, New York, NY) and the speciﬁc signal was revealedwith
a goat anti-rat IgG Alexia Fluor 568 conjugate (Invitrogen).
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